Lab21 opens syphilis testing pathways to India
This article was originally published in Clinica
UK diagnostics firm Lab21 has gained its first sales representatives in India after its immunodiagnostic division signed a distribution agreement with Spectral Diagnostics for its syphilis diagnostic test kits. Spectral, which is Inverness Medical Innovations’ distribution arm in India, will supply more than 500,000 of Lab21’s TPHA kits to the Indian Healthcare market over the next 18 months – the contract is worth approximately $1.1m of revenue for Lab21. The Cambridge-based firm said that India was the first of a number of new territories in which it planned to launch over the next twelve months. Financial terms of the deal were not disclosed.